Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds
- Nearly 2,000 drug manufacturing plants have not been inspected since the COVID-19 pandemic began, according to an investigation by The Associated Press .
- Over 340 overdue plants are located in India and China, which are key sources of drug ingredients for U.S. Prescriptions.
- The FDA has experienced staff shortages, contributing to the backlog of uninspected plants, as noted by Rogers.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left15Leaning Right1Center12Last UpdatedBias Distribution54% Left
Bias Distribution
- 54% of the sources lean Left
L 54%
C 42%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage